Johnson & Johnson has announced the European Commission Approval for a Preventative Ebola Vaccine, created by Janssen, its pharmaceutical company. This marks the first major regulatory approval of a vaccine developed by Janssen. The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology. Enabled by this approval, Janssen is now collaborating with the World Health Organisation (WHO) on vaccine pre-qualification, which should accelerate registration of its preventive Ebola vaccine regimen in African countries and facilitate broader access to those most in need.
“The approval of our Ebola vaccine symbolizes the progress Janssen has made towards achieving our vision of delivering potentially transformational vaccines to communities most at risk of deadly infectious diseases. Not only is it the first vaccine to emerge from our vaccines pipeline, it is also the first approved vaccine to be developed using Janssen’s AdVac® technology. The same technology is being used to develop vaccine candidates to protect against SARS-CoV-2, as well as Zika, RSV and HIV.” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
